Solara Pharma discusses Q1FY26 financial results
Solara Pharma discusses Q1FY26 financial results in its investor call. The company reviewed performance for the quarter ended June 30, 2026, highlighting revenue of ₹182.4 Cr and EBITDA at ₹34.1 Cr. Management discussed margin trends and R&D outlay of ₹12.5 Cr. Guidance for FY26 exports reiterated at $115–120 Mn.
📊 STOCKS: $SOLARA | 🏢 SECTOR: Pharma | #MEDIUMIMPACT #Earnings
This brief is AI-generated from public news sources for informational purposes only. Not investment advice. Always consult a SEBI-registered advisor before trading.